SKN | Barclays Initiates Helus Pharma Coverage With $35 Target Ahead of Key Clinical Readout

Key Takeaways:

• Barclays initiated coverage of Helus Pharma with an Overweight rating and a $35 price target, placing the bank’s research view ahead of a major clinical catalyst.
• The target reflects Barclays’ assessment of Helus’ development pipeline, particularly the late-stage HLP003 program targeting major depressive disorder.
• The APPROACH Phase 3 study is expected to deliver results in the fourth quarter, making the upcoming clinical readout a central factor in Barclays’ coverage framework.
• For sophisticated capital allocators, the significance of Barclays’ initiation lies in how the bank is framing clinical execution and regulatory milestones as the primary drivers of future valuation.

Barclays has initiated coverage of Helus Pharma with an Overweight rating and a $35 price target, establishing a formal institutional view on the pharmaceutical company ahead of an important late-stage clinical catalyst. The target compares with the stock’s Thursday close of roughly $14 and places Barclays’ valuation framework firmly around the company’s upcoming development milestones.

The timing is significant. Helus is approaching a major data event for HLP003, its deuterated psilocin candidate for major depressive disorder. For Barclays, the upcoming clinical evidence provides the key reference point for assessing the company’s development trajectory and potential path toward regulatory submission.

Barclays Builds Its Case Around HLP003

Barclays’ initiation comes as Helus prepares for results from the late-stage APPROACH study, which is evaluating HLP003 as an add-on treatment for major depression. The study completed enrollment in July and is expected to produce results during the fourth quarter.

HLP003 has received FDA Breakthrough Therapy status, adding regulatory significance to the program as Helus advances toward subsequent development stages. A second Phase 3 study, EMBRACE, and a long-term extension study are expected to follow the APPROACH readout.

Barclays’ $35 target therefore places substantial importance on the company’s ability to convert clinical progress into a credible regulatory pathway. Helus has indicated that, if the data support continued development, it aims to submit an application to the U.S. Food and Drug Administration in 2028.

The Bank’s Coverage Arrives Before a Major Valuation Test

The timing of Barclays’ research initiation gives its report particular relevance. Helus shares initially moved higher after the announcement, reaching a new 52-week high before reversing and trading near $12.50 by midday. The price action illustrates the sensitivity of the stock to expectations surrounding the clinical program.

Barclays is not building its coverage around a mature commercial franchise. Instead, the bank is assessing a development-stage pharmaceutical platform where clinical evidence, regulatory progression and future commercialization potential can materially influence valuation.

Helus has also raised $50 million through a June offering to fund its late-stage programs. Meanwhile, HLP004, its deuterated DMT candidate for anxiety, remains at an earlier stage following a mid-stage signal-finding study.

Why Barclays’ Initiation Matters for Capital Allocation

For sophisticated investors, the key issue is not simply Barclays’ $35 target but the risk structure behind that valuation. The bank’s coverage arrives before the APPROACH results, meaning the clinical data will become an important test of the assumptions supporting its outlook.

The next milestones are therefore clearly defined: the APPROACH results, subsequent Phase 3 development, regulatory progress and the eventual commercial pathway for HLP003. Barclays’ initiation places institutional attention on those milestones while highlighting the unusually binary nature of valuation in late-stage biotechnology.

For a confidential discussion regarding your cross-border banking structure, specialist-sector exposure or international wealth strategy, contact our senior advisory team.